Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial

被引：0

作者：

Broeckelmann, Paul J. ^{[1
]}

Buehnen, Ina ^{[1
]}

Herhaus, Peter ^{[2
]}

Meissner, Julia ^{[3
]}

Trautmann-Grill, Karolin ^{[4
]}

Mueller, Horst ^{[1
]}

Fuchs, Michael ^{[1
]}

von Tresckow, Bastian ^{[5
]}

Borchmann, Peter ^{[1
]}

Engert, Andreas ^{[1
]}

Behringer, Karolin ^{[1
]}

机构：

[1] Univ Hosp Cologne, Dept Internal Med, German Hodgkin Study Grp GHSG, Cologne, Germany

[2] Tech Univ Munich, Sch Med, Clin & Policlin Internal Med 3, Klinikum Rechts Isar, Munich, Germany

[3] Univ Hosp Heidelberg, Med 5, Heidelberg, Germany

[4] Univ Hosp Carl Gustav Carus, Med Clin 1, Dresden, Germany

[5] West German Canc Ctr Essen, Dept Hematol & Stem Cell Transplantat, Essen, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-189250

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group [J].

Eichenauer, Dennis A. ;

Pluetschow, Annette ;

Kreissl, Stefanie ;

Soekler, Martin ;

Hellmuth, Johannes C. ;

Meissner, Julia ;

Mathas, Stephan ;

Topp, Max S. ;

Behringer, Karolin ;

Klapper, Wolfram ;

Kuhnert, Georg ;

Dietlein, Markus ;

Kobe, Carsten ;

Fuchs, Michael ;

Diehl, Volker ;

Engert, Andreas ;

Borchmann, Peter .

LANCET ONCOLOGY, 2017, 18 (12) :1680-1687

[32] Salvage Treatment with Ofatumumab and ESHAP (O-ESHAP) for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma After First-Line Chemotherapy: Interim Analysis of a Phase II Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO) [J].

Martinez, Carmen ;

Rodriguez-Calvillo, Mercedes ;

Terol, Maria Jose ;

Xicoy, Blanca ;

Garcia-Sanz, Ramon ;

Perez-Ceballos, Elena ;

Cantalapiedra, Alberto ;

Domingo-Domenech, Eva ;

Hernandez, Miguel ;

Sampol, Antonia ;

Espeso, Manuel ;

Briones, Javier ;

Lopez, Javier ;

Sureda, Anna .

BLOOD, 2012, 120 (21)

[33] First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: Phase II trial [J].

Hainsworth, JD ;

Litchy, S ;

Lamb, MR ;

Rodriguez, GI ;

Scroggin, C ;

Greco, FA .

CLINICAL LYMPHOMA, 2003, 4 (01) :36-42

[34] Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial [J].

Behringer, K. ;

Thielen, I. ;

Mueller, H. ;

Goergen, H. ;

Eibl, A. D. ;

Rosenbrock, J. ;

Halbsguth, T. ;

Eichenauer, D. A. ;

Fuchs, M. ;

Reiners, K. S. ;

Renno, J. H. ;

van der Ven, K. ;

Kuehr, M. ;

von Wolff, M. ;

Diehl, V. ;

Engert, A. ;

Borchmann, P. .

ANNALS OF ONCOLOGY, 2012, 23 (07) :1818-1825

[35] Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma - a Phase II Clinical Trial [J].

Jain, Preetesh ;

Young, Chi ;

Nastoupil, Loretta J. ;

Westin, Jason ;

Hill, Holly A. ;

Nair, Ranjit ;

Iyer, Swami P. ;

Fetooh, Ahmed ;

Lee, Hun Ju ;

Ahmed, Sairah ;

Kanagal-Shamanna, Rashmi ;

Jelloul, Fatima Z. ;

Castillo, Luis Enrique Malpica ;

Liu, Yang ;

Li, Yijing ;

Vargas, Jovanny ;

Feng, Lei ;

Badillo, Maria ;

Thirumurthi, Selvi ;

Xu, Guofan ;

Deswal, Anita ;

Iliescu, Cezar ;

Nguyen, Vinh Quang ;

Tang, Guilin ;

Patel, Keyur P. ;

Vega, Francisco ;

Medeiros, L. Jeffrey ;

Wang, Michael L. ;

Flowers, Christopher R. .

BLOOD, 2023, 142

[36] Phase-II trial of rituximab in patients with relapsed CD20-positive Hodgkin's lymphoma: An update from the German Hodgkin's Lymphoma Study Group (GHSG). [J].

Schulz, H ;

Rehwald, U ;

Reiser, M ;

Ruediger, T ;

Morschhauser, F ;

Diehl, V ;

Engert, A .

BLOOD, 2002, 100 (11) :775A-775A

[37] Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial [J].

Cheson, Bruce D. ;

Bartlett, Nancy L. ;

LaPlant, Betsy ;

Lee, Hun J. ;

Advani, Ranjana J. ;

Christian, Beth ;

Diefenbach, Catherine S. ;

Feldman, Tatyana A. ;

Ansell, Stephen M. .

LANCET HAEMATOLOGY, 2020, 7 (11) :E808-E815

[38] Prospective analysis of factors influencing inclusion of 102 patients with advanced Hodgkin Lymphoma in a randomized trial for first-line chemotherapy [J].

Biasoli, I. ;

Franchi-Rezgui, P. ;

Sibon, D. ;

Briere, J. ;

de Kerviler, E. ;

Thieblemont, C. ;

Levy, V. ;

Brice, P. .

ANNALS OF ONCOLOGY, 2008, 19 :233-233

[39] PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma [J].

Collinson, F. ;

Brown, S. ;

Buckley, H. ;

Ainsworth, G. ;

Howard, H. ;

Poad, H. ;

Carr, G. ;

Banks, R. E. ;

Brown, J. ;

Velikova, G. ;

Larkin, J. ;

Nathan, P. ;

Powles, T. B. ;

Vasudev, N. S. .

ANNALS OF ONCOLOGY, 2018, 29

[40] Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy [J].

Rose, Tracy L. ;

Chism, David D. ;

Alva, Ajjai S. ;

Deal, Allison M. ;

Maygarden, Susan J. ;

Whang, Young E. ;

Kardos, Jordan ;

Drier, Anthony ;

Basch, Ethan ;

Godley, Paul A. ;

Dunn, Mary W. ;

Kim, William Y. ;

Milowsky, Matthew I. .

BRITISH JOURNAL OF CANCER, 2018, 119 (07) :801-807

← 1 2 3 4 5 →